Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.63 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 7/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26294134 | 1.00 | AHR (0.63) | AHRCFTRCYP11B1CYP11B2ABL1 | |
| SCHEMBL26294145 | 0.90 | AHR (0.51) | AHRCFTRACVR1TP53MAPT | |
| SCHEMBL26294121 | 0.90 | AHR (0.49) | AHRCFTRACVR1TP53MAPT | |
| SCHEMBL23390604 | 0.84 | AHR (0.45) | AHRACVR1 | |
| SCHEMBL26294345 | 0.84 | AHR (0.45) | AHRACVR1 | |
| SCHEMBL23390603 | 0.84 | AHR (0.45) | AHRACVR1 | |
| SCHEMBL25404965 | 0.83 | AHR (0.52) | AHRCFTRCYP11B1CYP11B2ABL1 | |
| SCHEMBL22430121 | 0.82 | AHR (0.69) | AHRCFTRCYP11B1CYP11B2ABL1 | |
| SCHEMBL25580216 | 0.82 | AHR (0.69) | AHRCFTRCYP11B1CYP11B2ABL1 | |
| SCHEMBL25403249 | 0.82 | AHR (0.44) | AHRCFTRACVR1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | AHR 1/4885CFTR 136/4885CYP11B1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.